Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 24 July, 2009

Lipoxen PLC

Audit and Remuneration Commit

RNS Number : 2856W
Lipoxen PLC
24 July 2009
 

For immediate release

24 July 2009


Lipoxen plc

('Lipoxen' or 'the Company')


Audit and Remuneration Committee Membership


Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, advises that in its Board meeting following its successful Annual General Meeting today, the Company has altered the membership of its Audit and Remuneration Committees. Committee membership is now as below.


Audit Committee:


Sir Brian Richards, Non-executive Director (Chairman)

Firdaus Jal Dastoor, Non-executive Director

M Scott Maguire, Chief Executive Officer


Remuneration Committee:


Sir Brian Richards, Non-executive Director (Chairman)

Firdaus Jal Dastoor, Non-executive Director

Colin William Hill, Chief Financial Officer


- Ends -

For further information please contact:


Lipoxen plc

+44 (0)20 7389 5015 

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 




Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  




Buchanan Communications

+44 (0)20 7466 5000

Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen



Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products.  


Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and Factor VIII through an exclusive license with Baxter, the global healthcare company.


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme. Furthermore, Baxter led the £2.9 million fundraising that the Company announced in May 2009, with a US$1 million investment.


Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRILFVRDVISFIA